Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
This article was originally published in The Pink Sheet Daily
Executive Summary
It's about being a "sower and a grower" not a "seeker and a picker," Zhang said of Lilly's FIPNET philosophy.
You may also be interested in...
Excited By Unique Capabilities Of Zydus Cadila, Eli Lilly Partners For Research In Cardiovascular Drugs
MUMBAI - After striking collaborative research deals with India's Piramal Life Sciences, Jubilant Organosys and Suven, U.S. drug giant Eli Lilly has added Zydus Cadila as its latest partner for drug discovery and development of new cardiovascular treatments
AstraZeneca Outsources Drug Discovery Research To BioDuro For Respiratory And Inflammation Indications
SHANGHAI - AstraZeneca is expanding its research collaboration with contract research organization BioDuro to cooperate on drug discovery research in respiratory and inflammation diseases in China, the two companies announced March 23
Network Group BayHelix Links Life Sciences Leaders To Blaze New Trail In China – An Interview With PharmAsia News (Part 2 of 2)
BayHelix is a non-profit, invitation-only organization for ethnic Chinese leaders in the global life sciences arena. Created in the San Francisco Bay Area in 2001, BayHelix has since become a bridge linking 300-plus Chinese business, law and science professionals in the health care industry across the U.S., Canada and Greater China. Recently the chairman of BayHelix, James Zhu, managing partner of Perkins Coie's Beijing Office, and the group's two co-founders, Jonathan Wang, OrbiMed's managing director in Asia, and Steve Yang, vice president, Head of Asia R&D at Pfizer, sat down with PharmAsia News' Shanghai Bureau to talk about the founding and the future of BayHelix as well as the challenges and opportunities in China's life sciences sector.